The group's principal activities are to acquire, develop and commercialise proprietary and generic drug products, primarily for the treatment of cancer and related disorders. The group operates in two divisions: oncology and general drug. The oncology division acquires rights to clinical-stage oncology drug candidates and either alone, or through alliances with other companies, develop and eventually commercialize those drugs. The general drug division sells generic versions of drugs whose patent protection expires in the near term.
